Durable Response to Glofitamab in HIV-Positive Refractory Burkitt Lymphoma: Case Report and Discussion.
[BACKGROUND] Refractory Burkitt lymphoma (BL) has a dismal prognosis after failure of frontline therapy.
APA
Elisa B, Theresa M, et al. (2026). Durable Response to Glofitamab in HIV-Positive Refractory Burkitt Lymphoma: Case Report and Discussion.. EJHaem, 7(1), e70243. https://doi.org/10.1002/jha2.70243
MLA
Elisa B, et al.. "Durable Response to Glofitamab in HIV-Positive Refractory Burkitt Lymphoma: Case Report and Discussion.." EJHaem, vol. 7, no. 1, 2026, pp. e70243.
PMID
41694088
Abstract
[BACKGROUND] Refractory Burkitt lymphoma (BL) has a dismal prognosis after failure of frontline therapy. New treatment options are urgently needed.
[METHODS] We describe a 60-year-old HIV-positive patient with refractory and secondary primary BL after frontline and salvage therapy failure, treated off-label with glofitamab successfully.
[RESULTS] Twelve cycles of glofitamab were well tolerated and led to complete metabolic remission confirmed by imaging and biopsy, sustained for nine months post-treatment.
[CONCLUSION] Glofitamab may represent a promising stand-alone option in relapsed BL, when conventional cytotoxic therapies are exhausted. : The authors have confirmed that clinical trial registration is not needed for this submission.
[METHODS] We describe a 60-year-old HIV-positive patient with refractory and secondary primary BL after frontline and salvage therapy failure, treated off-label with glofitamab successfully.
[RESULTS] Twelve cycles of glofitamab were well tolerated and led to complete metabolic remission confirmed by imaging and biopsy, sustained for nine months post-treatment.
[CONCLUSION] Glofitamab may represent a promising stand-alone option in relapsed BL, when conventional cytotoxic therapies are exhausted. : The authors have confirmed that clinical trial registration is not needed for this submission.